Parkhurst et al. [183] demonstrated a TCR-based therapeutic strategy where the modified CEA-reactive TCR cells showed an enhancement in tumor recognition in comparison with the wild-type T cells against human CRC cell lines. Here, CEACAM5 is linked to neoplasm.